New facility to serve as European base for Incyte’s drug development operations, and provides efficient access to key clinical trial experts and institutions.
Incyte Corporation (Nasdaq:INCY) announced that it will establish the new headquarters of Incyte Europe S.a.r.l (“Incyte Europe”) in Geneva, Switzerland. Incyte intends to use Incyte Europe as the base from which it will conduct its European clinical development operations, and expects to occupy the 9,000 sq. ft. facility by mid-2015.
“The establishment of Incyte Europe in Geneva is a natural step in our company’s evolution,” said Hervé Hoppenot, President and CEO of Incyte Corporation. “Incyte has a broad and growing pipeline of proprietary, wholly-owned products, and we expect that this new facility in the center of Europe will enable us to create the infrastructure needed to support our global drug development programs, and to bring additional, potentially life-changing medicines to patients with cancer.”
“Geneva is especially pleased to welcome a biotechnology leader such as Incyte to our city,” said, Mr. Pierre Maudet, Minister of the Department of Security and Economy for the Republic and Canton of Geneva. “We are confident that Incyte will benefit from the international talent pool in Geneva and the surrounding region, and that the company’s presence will further enhance Geneva’s standing as an important hub in the biotechnology industry.”